Results 41 to 50 of about 11,727 (181)

Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. [PDF]

Molecular and Cellular Biology, 1991
Chronic myelogenous leukemia and one type of acute lymphoblastic leukemia are characterized by a 9;22 chronosome translocation in which 5' sequences of the bcr gene become fused to the c-abl proto-oncogene. The resulting chimeric genes encode bcr/abl fusion proteins which have deregulated tyrosine kinase activity and appear to play an important role in
J R, McWhirter, J Y, Wang
openaire   +2 more sources

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome

Revista Brasileira de Hematologia e Hemoterapia, 2012
OBJECTIVE: This study aimed to verify the association between human leukocyte antigens and the bcr-abl fusion protein resulting from t(9;22)(q34;q11) in chronic leukemia myeloid and acute lymphoblastic leukemia patients.
Daiana Landenberger de Carvalho, Cristian Dias Barbosa, André Luiz de Carvalho, Sandra Trevisan Beck   +3 more
doaj   +1 more source

Apoptosis resistance in chronic myelogenous leukemia [PDF]

Einstein (São Paulo), 2005
The chronic myeloid leukemia (CML) is the three-phasemyeloproliferative disorder, dependent on the expression of theoncoprotein Bcr-Abl, which is the product of the reciprocaltranslocation between chromosomes 9 and 22, resulting in thePhiladelphia ...
Fabíola Attié de Castro, Jacqueline de Fátima Jacysyn, Ana Elisa Bueno-da-Silva, Nelson Hamerschlak, Gustavo Pessini Amarante-Mendes   +4 more
doaj  

Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides

, 2012
In acute promyelocytic leukemia (APL), hematopoietic differentiation is blocked and immature blasts accumulate in the bone marrow and blood. APL is associated with chromosomal aberrations, including t(15;17) and t(11;17).
Sabine Beez (123610), Beez, Sabine, Philipp Demmer, Elena Puccetti (66633), Philipp Demmer (123611), Puccetti, Elena, Elena Puccetti, Sabine Beez, Demmer, Philipp   +8 more
core   +1 more source

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins [PDF]

Blood, 1997
CGP 57148 is a compound of the 2-phenylaminopyrimidine class that selectively inhibits the tyrosine kinase activity of the ABL and the platelet-derived growth factor receptor (PDGFR) protein tyrosine kinases. We previously showed that CGP 57148 selectively kills p210BCR-ABL–expressing cells. To extend these observations, we evaluated the ability of CGP
M, Carroll, S, Ohno-Jones, S, Tamura, E, Buchdunger, J, Zimmermann, N B, Lydon, D G, Gilliland, B J, Druker   +7 more
openaire   +3 more sources

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor β gene

Haematologica, 2007
Background and Objectives We sought to identify new fusion genes with involvement of the platelet-derived growth factor receptor β gene (PDGFRB) in three patients presenting with various subtypes of chronic myeloproliferative disorders associated with ...
Christoph Walz, Georgia Metzgeroth, Claudia Haferlach, Annette Schmitt-Graeff, Alice Fabarius, Volker Hagen, Otto Prümmer, Stefan Rauh, Rüdiger Hehlmann, Andreas Hochhaus, Nicholas C.P. Cross, Andreas Reiter   +11 more
doaj   +1 more source

Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes [PDF]

Leukemia, 2002
Although CD4(+) helper T lymphocytes have been demonstrated to play an important role in antitumor immune response, only a few epitopes of tumor-associated antigens recognized by HLA class II-restricted CD4(+) T lymphocytes have been identified.
M, Makita, T, Azuma, H, Hamaguchi, H, Niiya, K, Kojima, S, Fujita, M, Tanimoto, M, Harada, M, Yasukawa   +8 more
openaire   +2 more sources

Self-assembled Human Serum Protein-based Core-shell Nanoparticles to inhibit key oncogenic signalling in Drug-Resistant Leukemia

Precision Nanomedicine
Simultaneous inhibition of multiple oncogenic signaling pathways is crucial for managing refractory cancers. This study introduces two unique core-shell nanoparticle (CS-NP) systems crafted from natural proteins that simultaneously target two crucial ...
Archana Payickattu Retnakumary, Lekshmi G Kumar, Neeraj Sidharthan, Pavithran Keechilat, Giridharan L. Malarvizhi, Prasanna L Hanumanthu, Madhavan V Thampi, Deepthy Menon, Krishnakumar Menon, Shantikumar V Nair, Manzoor Koyakutty   +10 more
doaj   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia

Cells, 2019
Leukemias bearing mixed lineage leukemia (MLL) rearrangement (MLL-R) resulting in expression of oncogenic MLL fusion proteins (MLL-FPs) represent an especially aggressive disease subtype with the worst overall prognoses and chemotherapeutic response. MLL-
Aditya Barve, Alexis Vega, Parag P. Shah, Smita Ghare, Lavona Casson, Mark Wunderlich, Leah J. Siskind, Levi J. Beverly   +7 more
doaj   +1 more source